hematopoietic and lymphoid malignancies
Conditions
Interventions
Intervention Group:Car-T cells
Sponsors
Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.The treat history meeting the following criteria: 1) Recurrence of lymphoma patients with imaging (CT/MRI/PET-CT) detection and pathological diagnosis, or recurrence including bone marrow morphology relapse and the MRD recurrence of myeloma patients or leukemia patients, after chemotherapy or stem cell transplantation; 2) Can't get complete remission (including MRD positive) after more than twice repeated chemotherapy of incipient lymphoma, myeloma or leukemia patients; 3) One or twice chemotherapy cannot get remission again (including MRD positive), but not suitable for chemotherapy of incipient lymphoma, myeloma or leukemia patients. 2. There is a measurable lesions before treatment at least; 3. ECOG score=2; 4. To be aged 1 to 70 years; 5. More than a month lifetime from the consent signing date
Exclusion criteria
Exclusion criteria: 1. Serious cardiac insufficiency, left ventricular ejection fraction<50; 2. Has a history of severe pulmonary function damaging; 3. Merging other malignant tumor; 4. Merging uncontrolled infection; 5. Merging the metabolic diseases (except diabetes); 6. Merging severe autoimmune diseases or immunodeficiency disease; 7. patients with active hepatitis B or hepatitis C; 8. patients with HIV infection; 9. Has a history of serious allergies on Biological products (including antibiotics); 10. Happened in 3 ~ 4 acute GvHD after allogeneic hematopoietic stem cell transplantation on recurring patients 11. Pregnancy or lactation women; 12. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate;overall response rate;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Countries
China
Contacts
Public ContactLiu Lihong
Fourth Hospital of Hebei Medical University
Outcome results
None listed